- Conditions
- Multiple Myeloma
- Interventions
- Ascorbate, Melphalan
- Other · Drug
- Lead sponsor
- Christopher Strouse
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Overactive Bladder
- Interventions
- Fesoterodine, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 896 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 95
- States / cities
- Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
- Conditions
- Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
- Interventions
- ANG003 Dose A, ANG003 Dose B, Creon
- Drug
- Lead sponsor
- Anagram Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 27
- States / cities
- Long Beach, California • Los Angeles, California • Denver, Colorado + 23 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2038
- U.S. locations
- 999
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
- Conditions
- Glioma
- Interventions
- Rhenium Liposome Treatment
- Drug
- Lead sponsor
- Cerenome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 3
- States / cities
- Manhasset, New York • Dallas, Texas • San Antonio, Texas
- Conditions
- Liver Transplantation
- Interventions
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Baltimore, Maryland + 6 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
- Drug · Radiation
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ixabepilone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 3
- States / cities
- San Antonio, Texas
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Interventions
- Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 27
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more
- Conditions
- Burns
- Interventions
- Vitamin K
- Drug
- Lead sponsor
- Joseph M. Still Research Foundation, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Depression
- Interventions
- lithium and Venlafaxine, ECT
- Drug · Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 10
- States / cities
- Augusta, Georgia • Rochester, Minnesota • Hoboken, New Jersey + 6 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- DEC-C, MyeloSeq-HD
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- ADHD
- Interventions
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Knee Osteoarthritis
- Interventions
- Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
- Interventions
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
- Drug · Device
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
- Interventions
- TSD-001
- Drug
- Lead sponsor
- Lipac Oncology LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
- Conditions
- HCV Infection
- Interventions
- VCH 916, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Dallas, Texas • San Antonio, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- ASTX727, Venetoclax
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Disc Degeneration
- Interventions
- MSC Treatment group 1 (low dose), MSC Treatment group 2 (high dose), Healthy Control (no treatment)
- Drug · Other
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna
- Drug · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab, Antihistamine, Methylprednisolone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 25
- States / cities
- Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more
- Conditions
- Melanoma
- Interventions
- ALS-357
- Drug
- Lead sponsor
- Advanced Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neuroblastoma, Ganglioneuroblastoma
- Interventions
- Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 18 Months to 26 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2038
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Narcotic Addiction, Neonatal Abstinence Syndrome
- Interventions
- Ondansetron, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 45 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 8
- States / cities
- San Francisco, California • San Jose, California • Stanford, California + 5 more